

[Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.](#)

Zesiewicz T, Salemi JL, Perlman S, Sullivan KL, Shaw JD, Huang Y, Isaacs C, Gooch C, Lynch DR, Klein MB.

*Neurodegenerative Disease Management*. 2018 Aug;8(4):233-242. doi: 10.2217/nmt-2018-0013. Epub 2018 Jul 27.

[Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.](#)

Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F.

*Annals of Neurology*. 2014 Oct;76(4):509-21. doi: 10.1002/ana.24248. Epub 2014 Aug 30.

[Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.](#)

Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR.

*Journal of Neurology*. 2012 Feb;259(2):284-91. doi: 10.1007/s00415-011-6174-y. Epub 2011 Jul 22.

[Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.](#)

Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Balcer LJ, Wilson RB, Lynch DR.

*Movement Disorders*. 2010 Mar 15;25(4):426-32. doi: 10.1002/mds.22912.

[Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.](#)

Di Prospero NA, Baker A, Jeffries N, Fischbeck KH.

*The Lancet Neurology*. 2007 Oct;6(10):878-86.

[Measuring Friedreich ataxia: complementary features of examination and performance measures.](#)

Lynch DR, Farmer JM, Tsou AY, Perlman S, Subramony SH, Gomez CM, Ashizawa T, Wilmot GR, Wilson RB, Balcer LJ.

*Neurology*. 2006 Jun 13;66(11):1711-6.

[Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale.](#)

Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, Taylor P, Wilson R, Ashizawa T; Cooperative Ataxia Group.

*Neurology*. 2005 Apr 12;64(7):1261-2.